Sign In

Mayank Barg

Project Manager / Pharmacovigilance / Aggregate reporting / ICSR / Mailbox / RMP

Mayank Barg is currently the Project Manager for Aggregate Reports at Vigilare Biopharma Pvt Ltd, where he has developed a robust career in pharmacovigilance and aggregate reporting over the past 12 years. His expertise includes signal detection and the management of individual case safety reports (ICSRs) within the pharmaceutical industry.

He holds an M. Pharma degree and has previously worked in various roles related to pharmacovigilance, contributing significantly to the field through his knowledge and experience.13 His professional profile indicates a strong commitment to improving drug safety and regulatory compliance, making him a valuable asset in his current position at Vigilare Biopharma.2

Highlights

Sep 29 · linkedin

NDA filling requirement:

Filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) is a comprehensive and complex process that involves compiling a substantial amount of data and documentation to demonstrate the safety and efficacy of a new drug. Here is an overview of the key requirements and components involved in filing an NDA:

Cover Letter: Provide a cover letter that introduces the NDA submission and includes information about the applicant, contact details, and a brief overview of the submission.

Table of Contents: Include a comprehensive table of contents that outlines the structure of the NDA submission.

Administrative Information: Include forms such as Form FDA 356h (Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use) and user fees.

Summary: Prepare a summary of the NDA submission that provides a concise overview of the drug's development, its indications, safety, efficacy, and a risk-benefit assessment.

Chemistry, Manufacturing, and Controls (CMC) Information: Provide detailed information about the drug's composition, manufacturing process, and controls to ensure quality, safety, and consistency. Include data on drug substance and product characterization, stability studies, and manufacturing facilities.

Preclinical Data: Include preclinical data from laboratory studies and animal models that support the safety and potential efficacy of the drug.

Clinical Data: Include comprehensive clinical trial data, including protocols, investigator brochures, clinical study reports, and statistical analyses. Summarize data related to the drug's safety profile, efficacy, pharmacokinetics, and patient populations.

Safety Data: Present data on adverse events, serious adverse events, and post-marketing surveillance findings. Include a comprehensive analysis of the drug's safety profile.

Labeling: Provide proposed labeling information, including the prescribing information, package inserts, and patient information leaflets.

Patent Information: Include information about any patents that cover the drug, its formulations, and methods of use.

Risk Evaluation and Mitigation Strategies (REMS): If required, provide a plan to manage risks associated with the drug, including communication plans and strategies to ensure safe use.

Electronic Submission: NDA submissions are typically submitted electronically through the Common Technical Document (eCTD) format.

Payment of User Fees: Pay the required user fees associated with NDA submission.

Post-Submission Interaction: Be prepared to respond to FDA queries, requests for additional information, and potential advisory committee meetings.

Review and Approval: The FDA reviews the NDA submission thoroughly, and provide approval.

Filing an NDA is a complex and critical process that requires expertise in regulatory affairs, data analysis, and drug development. It's essential to adhere to FDA guidelines, regulations, and submission requirements.

Sep 29 · linkedin

#drugsafety #pharmacovigilance #cro

Related Questions

What are Mayank Barg's key achievements in pharmacovigilance?
How has Mayank Barg contributed to Vigilare Biopharma's growth?
What specific projects has Mayank Barg managed at Vigilare Biopharma?
What is Mayank Barg's educational background?
How does Mayank Barg stay updated with industry trends in pharmacovigilance?
Mayank Barg
Mayank Barg, photo 1
Mayank Barg, photo 2
Add to my network

Location

Hyderabad, Telangana, India